Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

@article{Wong2000ReboxetineAP,
  title={Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor},
  author={E. Wong and M. Sonders and S. Amara and Paula M Tinholt and M. Piercey and William P. Hoffmann and D. K. Hyslop and S. Franklin and R. Porsolt and A. Bonsignori and N. Carfagna and R. Mcarthur},
  journal={Biological Psychiatry},
  year={2000},
  volume={47},
  pages={818-829}
}
BACKGROUND Reboxetine is a potent antidepressant, with efficacy comparable to that of imipramine, desipramine, and fluoxetine, and has improved side-effect profile. The basis of its efficacy and improved tolerability is sought through studies of reboxetine in a number of pharmacological models of depression. METHODS Pharmacological selectivity for uptake systems was defined by uptake and binding assays for the three monoamine uptake sites. Specificity was determined in 39 different receptor… Expand
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
TLDR
In vitro and in vivo pharmacological studies indicated that reboxetine methanesulphonate has high affinity and selectivity for the human norepinephrine transporter over the serotonin and dopamine transporters, which has provided the psychopharmacology community with a tool to elucidate the role of nore Alpinephrine in brain functions. Expand
The promises and pitfalls of reboxetine.
  • M. Page
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
TLDR
Reboxetine has been a valuable pharmacological tool to assess the role of the noradrenergic system in preclinical studies of depressive disorder and its use as an antidepressant is currently limited to Europe. Expand
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats
TLDR
In parallel with an elevation in extracellular levels of NE, the selective NE reuptake inhibitor, reboxetine, elicits a specific discriminative stimulus in rats. Expand
Synthetic Story of a Blockbuster Drug: Reboxetine, a Potent Selective Norepinephrine Reuptake Inhibitor
α-Aryloxybenzyl analogues of morpholine are a significant class of compounds because of their influence on the central nervous system (CNS), with particular concentration on their antidepressantExpand
Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
  • M. Millan, A. Dekeyne
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
DS properties of reboxetine are mimicked by antidepressants recognizing NE transporters, and require functionally intact alpha1-ARs for their expression. Expand
Regulatory Effects of Reboxetine Treatment Alone, or Following Paroxetine Treatment, on Brain Noradrenergic and Serotonergic Systems
TLDR
Pretreatment of rats with PRX actually enhanced at least one regulatory effect ofRBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment. Expand
The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram
TLDR
The present study strongly supports the hypothesis that a specific blockade of norepinephrine reuptake is more potent in treating cataplexy than a Specific blockade of serotonin reuptakes, and argues for the development of more specific nore Alpinephrine reptake inhibitors for the treatment of narcolepsy. Expand
Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.
TLDR
In addition to inhibition of NET function, reboxetine inhibits nAChR function, suggesting that it may have potential as a smoking cessation agent. Expand
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
TLDR
In conclusion, in line with its inhibition of 5-HT and (less potently) NE reuptake, S33005 is active in a broad range of models suggestive of antidepressant activity and exerts its actions more potently than venlafaxine and clomipramine, and its overall profile is distinct from those of citalopram and reboxetine. Expand
l-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats
TLDR
Results indicate that l-DOPA modifies the effect of SSRI and NRI antidepressants in opposing ways. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
TLDR
Results indicate that changes to 8-OH-DPAT and clonidine-induced responses occur quicker with the combination treatment than with either reboxetine or sertraline treatments alone, and also indicates changes to 5-HT1A receptor and alpha2-adrenoceptor sensitivity. Expand
Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor
TLDR
Reboxetine seems to be an antidepressant with negligible interference with the pharmacokinetics of other drugs thus fewer drug-drug interactions are expected. Expand
Preclinical evidence on the psychotropic profile of fluvoxamine.
TLDR
Results of studies of the mechanism of action of fluvoxamine in which drug discrimination tests were performed with rats and pigeons suggest that the flu voxamine stimulus is not (or is only to a very limited degree) dependent on activation of 5-HT1A receptors or 5- HT1B/1D receptors, or both. Expand
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.
TLDR
The preclinical profile of nefazodone demonstrates that it has decreased anticholinergic and antihistaminic activity relative to traditional agents, which may be beneficial for treating symptoms of depression as evidenced by recent clinical findings. Expand
Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
TLDR
Clinical experience has demonstrated all three drugs to be effective in treatment of depression, and paroxetine, sertraline, and fluvoxamine may be especially useful in elderly patients, in those who cannot tolerate alternative treatments, and in Those who do not respond to adequate trials of other antidepressant therapies. Expand
Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo.
TLDR
Previous in vitro and in vivo data reporting nefazodone to be an antagonist at 5HT2A receptors, but fail to show inhibition of the 5HT uptake carrier in the same dose range are reported. Expand
Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes
Abstract A 6-week, randomised, double-blind, multicentre study in 256 patients with a DSM-III-R diagnosis of major depression was carried out to compare the selective noradrenaline reuptake inhibitorExpand
Clinical overview of serotonin reuptake inhibitors.
TLDR
Serotonin reuptake inhibitors have not replaced the tricyclics, but are a useful addition to the variety of drugs currently used for the treatment of depression. Expand
Do noradrenaline and serotonin differentially affect social motivation and behaviour?
TLDR
A differential effect of selective manipulation of the noradrenergic or serotonergic system is supported, at social functioning level, in keeping with the long-debated hypothesis on the specific involvement of serotonin in regulating mood and of Noradrenaline in sustaining drive. Expand
Bupropion: a review of its mechanism of antidepressant activity.
TLDR
The mechanism of action of buPropion appears to have an unusual, not fully understood, noradrenergic link, and the mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms. Expand
...
1
2
3
4
5
...